A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma.
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Everolimus (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 Jun 2012 Actual end date changed from Dec 2010 to Dec 2009 as reported by ClinicalTrials.gov.
- 10 Dec 2010 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.